On October 21, 2022 Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR artificial intelligence ("A.I.") and machine learning ("M.L.") platform to transform the cost, pace, and timeline of oncology drug discovery and development, reported that Lantern management will be presenting at the ThinkEquity Conference, which is being held on October 26th, 2022 in New York, NY (Press release, Lantern Pharma, OCT 21, 2022, View Source [SID1234622269]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Panna Sharma, Lantern’s CEO & President, will be hosting an A.I. and Drug Development Panel at 10:00 a.m. ET focused on how A.I. is transforming the cost, pace, and risks involved in developing a new drug.

Panelists will include noted experts from Weill Cornell, Volastra Therapeutics, InveniAI, and Hepion Pharmaceuticals.
Lantern Pharma is scheduled to present at the conference on Wednesday, October 26th at 1:00 p.m. ET.
Webcast Link: View Source
Registration Link: View Source
Lantern Pharma management will be available for one-on-one meetings to be held throughout the conference.